 |
Dendreon Announces First Quarter 2013 Results
May 9, 2013
|
24.9 KB |
|
| |
Conference Call to be Hosted May 9, 2013 at 9:00 a.m. ET
SEATTLE--(BUSINESS WIRE)--
May 9, 2013--Dendreon Corporation (Nasdaq:DNDN) today reported results
for the first quarter ended March 31, 2013. Net product revenue for the
quarter was $67.6 million compared to $82.0 million for the quart...
|
|
PROVENGE® (sipuleucel-T) Data Presented at An Annual Scientific Urology Meeting
May 6, 2013
|
16.5 KB |
|
| |
Three Presentations Inform the Use of PROVENGE in the Metastatic
Castrate-Resistant Prostate Cancer Treatment Continuum
SEATTLE--(BUSINESS WIRE)--
May 6, 2013--Dendreon Corporation (NASDAQ: DNDN)
today announced the presentation of three PROVENGE®
(sipuleucel-T) abstracts from ...
|
|
Dendreon to Host Conference Call on May 9 to Announce First Quarter Financial Results
Apr 24, 2013
|
12.7 KB |
|
| |
-- Company Announces Webcast Presentations at Upcoming Conferences --
SEATTLE--(BUSINESS WIRE)--
April 24, 2013--Dendreon Corporation (Nasdaq: DNDN) today announced that
management will host a conference call on Thursday, May 9, 2013, at 9:00
a.m. EDT to review first quarter financial result...
|
|
Dendreon Announces Securities Class Action Settlement
Mar 18, 2013
|
13.0 KB |
|
| |
SEATTLE--(BUSINESS WIRE)--
Dendreon Corporation (Nasdaq:DNDN) today announced that it has reached
an agreement in principle to settle the securities class action
litigation pending against it in the United States District Court for
the Western District of Washington. Upon final approval, the settlement
w...
|
|
Dendreon Announces Webcast Presentation at ROTH Conference
Mar 12, 2013
|
9.7 KB |
|
| |
SEATTLE--(BUSINESS WIRE)--
March 12, 2013—Dendreon Corporation (NASDAQ:DNDN) today announced that
management will present at the 25th Annual ROTH Conference in
Laguna Niguel, California, on March 18, 2013, at 11:00 a.m. PT.
The presentation will be webcast live and available for replay from
...
|
|
Dendreon Announces Fourth Quarter and 2012 Year End Results
Feb 25, 2013
|
30.6 KB |
|
| |
— Conference Call to be Hosted February 25, 2013 at 9:00 a.m. ET —
SEATTLE--(BUSINESS WIRE)--
Dendreon Corporation (Nasdaq: DNDN) today reported results for the
fourth quarter and full year ended December 31, 2012. Net product
revenue for the year ended December 31, 2012 was $325...
|
|
New PROVENGE® (sipuleucel-T) Data to Be Presented at 2013 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium
Feb 13, 2013
|
30.5 KB |
|
| |
-- Two studies examine potential for PROVENGE in combination or
sequenced with two approved advanced prostate cancer therapies
-- Additional retrospective study data suggest that relative to
placebo, PROVENGE may delay time to first opioid use for pain in
patients with advanced prostate cancer
...
|
|
Dendreon to Host Conference Call on February 25 to Announce Fourth Quarter and Full Year 2012 Financial Results and Webcast Presentations at Upcoming Conferences
Jan 30, 2013
|
12.5 KB |
|
| |
SEATTLE--(BUSINESS WIRE)--
Dendreon Corporation (Nasdaq: DNDN) today announced that management will
host a conference call on Monday, February 25, 2012, at 9:00 a.m. ET to
review fourth quarter and full year 2012 financial results.
Access to the discussion may be obtained as follows:
...
|
|
Dendreon Announces Preliminary Fourth Quarter 2012 Revenues
Jan 7, 2013
|
15.2 KB |
|
| |
SEATTLE--(BUSINESS WIRE)--
Dendreon Corporation (NASDAQ: DNDN) today announced preliminary revenues
for the fourth quarter ended December 31, 2012. Net product revenue for
the quarter is expected to be approximately $85.5 million, which
includes an approximate $3.8 million favorable adjustment to the
Com...
|
|
Dendreon Sells New Jersey Immunotherapy Manufacturing Facility
Dec 20, 2012
|
14.0 KB |
|
| |
BRIDGEWATER, N.J.--(BUSINESS WIRE)--
Dendreon Corporation (NASDAQ: DNDN) today announced the sale of its
immunotherapy manufacturing facility (IMF) based in Morris Plains, New
Jersey, to Novartis Pharmaceuticals Corporation for $43 million in cash.
"This agreement represents a positive outcome for...
|
|
Dendreon Announces Webcast Presentations at Upcoming Conferences
Nov 27, 2012
|
9.6 KB |
|
| |
SEATTLE--(BUSINESS WIRE)--
November 27, 2012--Dendreon Corporation (Nasdaq:DNDN) today
announced that management will present at the following conferences:
2012 dbAccess BioFEST in Boston, MA, on December 4, 2012, at 2:15 p.m.
ET
31st Annual J.P. Morgan...
|
|
Dendreon Appoints Lindsay Rocco to Lead Corporate Communications
Nov 14, 2012
|
11.0 KB |
|
| |
BRIDGEWATER, N.J.--(BUSINESS WIRE)--
Dendreon Corporation (NASDAQ: DNDN) today announced the appointment of
Lindsay Rocco as executive vice president, corporate communications and
member of the executive committee, effective immediately. In this role,
Ms. Rocco will be responsible for all communications functions...
|
|
Dendreon Announces Third Quarter 2012 Results
Nov 2, 2012
|
27.9 KB |
|
| |
— Restructuring on Track —
— Conference Call to be Hosted November 2, 2012 at 9:00 a.m. ET —
SEATTLE--(BUSINESS WIRE)--
November 2, 2012 — Dendreon Corporation (Nasdaq: DNDN) today
reported results for the quarter ended September 30, 2012. Net pr...
|
|
Dendreon Reschedules Third Quarter 2012 Results to November 2 Due to Hurricane Sandy
Oct 29, 2012
|
10.6 KB |
|
| |
SEATTLE--(BUSINESS WIRE)--
October 29, 2012—Dendreon Corporation (Nasdaq: DNDN) today
announced that in light of Hurricane Sandy, the Company has rescheduled
the release of its third quarter 2012 earnings results. Certain members
of its senior management team and commercial operations are in the
Co...
|
|
Dendreon to Host Conference Call on October 30 to Announce Third Quarter Financial Results and Webcast Presentations at Upcoming Conferences
Oct 5, 2012
|
11.4 KB |
|
| |
SEATTLE--(BUSINESS WIRE)--
October 5, 2012—Dendreon Corporation (Nasdaq:DNDN) today announced that
management will host a conference call on Tuesday, October 30, 2012, at
9:00 a.m. ET to review third quarter financial results.
Access to the discussion may be obtained as follows:
...
|
|
Dendreon to Present at 3rd Annual Cancer Immunotherapy Conference in New York
Oct 3, 2012
|
10.2 KB |
|
| |
SEATTLE--(BUSINESS WIRE)--
October 3, 2012 — Dendreon Corporation (NASDAQ:DNDN) today
announced the company will be presenting at the MD Becker Partners' 3rd
Annual Cancer Immunotherapy: A Long-Awaited Reality conference taking
place from 8:00 a.m. to 6:30 p.m. EDT on October 4, 2012, at the New
Yo...
|
|
First Patient In Dendreon EU Open-Label Study Begins Sipuleucel-T Infusion Treatment
Sep 28, 2012
|
13.7 KB |
|
| |
Sipuleucel-T Data To Be Presented At The ESMO 2012 Congress (European
Society for Medical Oncology)
SEATTLE--(BUSINESS WIRE)--
September 27, 2012--Dendreon Corporation (NASDAQ:DNDN)
today announced the first patient enrollment and initiation of treatment
for the sipuleucel-T Europea...
|
|
Dendreon Announces Webcast Presentations at Upcoming Conferences
Aug 24, 2012
|
9.8 KB |
|
| |
SEATTLE--(BUSINESS WIRE)--
August 24, 2012--Dendreon Corporation (Nasdaq:DNDN) today announced that
management will present at the following conferences:
Stifel Nicolaus 2012 Global Healthcare Conference in Boston, MA, on
September 5, 2012, at 3:50 p.m. ET
...
|
|
Dendreon Announces Second Quarter 2012 Results
Jul 30, 2012
|
27.2 KB |
|
| |
-- Company Announces Strategic Restructuring to Accelerate Path to
Profitability and Future Growth —-
-- Conference Call to be Hosted July 30, 2012 at 4:30 p.m. ET/1:30
p.m. PT --
SEATTLE--(BUSINESS WIRE)--
July 30, 2012--Dendreon Corporation (NASDAQ:DNDN) toda...
|
|
Dendreon Announces Strategic Restructuring to Accelerate Path to Profitability and Future Growth
Jul 30, 2012
|
18.5 KB |
|
| |
Projected Annual Cost Savings of Approximately $150 Million
Company Expects to be Cash-Flow Positive at Approximately $100
Million in Quarterly Net Product Revenue
SEATTLE--(BUSINESS WIRE)--
July 30, 2012--Dendreon Corporation (Nasdaq:DNDN) today announced a
strategi...
|
|
|
Delicious
Digg
Facebook
LinkedIn
Twitter